Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.

We strive to transform the rare blood disorder landscape by boldly reimagining treatment expectations through disruptive science and a patient-first approach. Our portfolio of products and innovative pipeline of early- to late-stage clinical development therapies focus on addressing persistent unmet patient needs through breakthrough technologies, including siRNA and BTK inhibitors. Inspired by patients and driven by science, we are focused on helping to make a transformative difference in the standard of care for people affected by rare blood disorders around the world. Learn more at www.sanofi.com.

Join the below Symposium and Presentation Theater sessions and please visit our Medical and Commercial virtual booths to learn more about what Sanofi Genzyme Rare Blood Disorders has to offer. Access will be available starting July 11 with a valid ISTH2021 Registration.